Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease.

The properties of control and 370Asn-->Ser glucocerebrosidase, the frequently encountered mutated form of the enzyme in type 1 Gaucher disease, were studied in vitro as well as in situ. The catalytic properties of purified 370Asn-->Ser glucocerebrosidase were highly dependent on the assay conditions. The enzyme was deficient in activity towards substrate and in reactivity with the irreversible inhibitor conduritol B-epoxide (CBE) when activated by the bile salt taurocholate. In the presence of more physiological activators, the lysosomal activator protein saposin C and phosphatidylserine, the 370Asn-->Ser enzyme was near normal in kinetic properties at pH values approximately 5, but not at higher pH. In intact fibroblasts, the enzymic activity of the 370Asn-->Ser glucocerebrosidase and its reactivity with CBE were found to be clearly deficient. However, in intact lymphoblasts from the same patients, the behavior of the mutant enzyme was near normal. The catalytic efficiency of 370Asn-->Ser glucocerebrosidase in situ was also found to be highly pH dependent. When intact lymphoblasts were cultured in the presence of permeant weak bases, which increase the pH of acidic intracellular compartments, the catalytic efficiency of the mutant enzyme, as assessed by its reactivity with CBE, became markedly impaired. Our findings indicate that the intralysosomal pH in the intact cell can be expected to have a critical influence on the activation state of 370Asn-->Ser glucocerebrosidase and its ability to hydrolyse substrate. This phenomenon may partly underly the marked heterogeneity in clinical manifestation of Gaucher disease among patients with this mutated form of glucocerebrosidase.

[1]  E. Beutler.  Gaucher disease: new molecular approaches to diagnosis and treatment. , 1992, Science.

[2]  S. Tsuji,et al.  DNA mutation analysis of Gaucher patients. , 1992, American journal of medical genetics.

[3]  E. Beutler,et al.  Mutations in Jewish patients with Gaucher disease. , 1992, Blood.

[4]  E. Beutler,et al.  Identification of the second common Jewish Gaucher disease mutation makes possible population-based screening for the heterozygous state. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[5]  E. Beutler,et al.  High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews. , 1991, American journal of human genetics.

[6]  M. Horowitz,et al.  Gaucher disease: heterologous expression of two alleles associated with neuronopathic phenotypes. , 1991, American Journal of Human Genetics.

[7]  J. Goldblatt,et al.  Clinical phenotype of Gaucher disease in relation to properties of mutant glucocerebrosidase in cultured fibroblasts. , 1991, Biochimica et biophysica acta.

[8]  E. Beutler,et al.  A Case of Nonneurologic Gaucher's Disease that Biochemically Resembles the Neurologic Types , 1991, Journal of neuropathology and experimental neurology.

[9]  Y. Kishimoto,et al.  Saposin proteins: structure, function, and role in human lysosomal storage disorders , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  S. Weiler,et al.  Characterization of human glucocerebrosidase from different mutant alleles. , 1991, The Journal of biological chemistry.

[11]  B. Theophilus,et al.  Heterogeneity of mutations in the acid beta-glucosidase gene of Gaucher disease patients. , 1991, DNA and cell biology.

[12]  J. Barranger,et al.  Conditions affecting the activity of glucocerebrosidase purified from spleens of control subjects and patients with type 1 Gaucher disease. , 1990, Biochimica et biophysica acta.

[13]  J. Barranger,et al.  Activity of glucocerebrosidase in extracts of different cell types from type 1 Gaucher disease patients , 1990, Clinical genetics.

[14]  U. Pettersson,et al.  Gaucher disease type III (Norrbottnian type) is caused by a single mutation in exon 10 of the glucocerebrosidase gene. , 1990, American journal of human genetics.

[15]  S. Brul,et al.  Comparative study on glucocerebrosidase in spleens from patients with Gaucher disease. , 1990, The Biochemical journal.

[16]  S. Weiler,et al.  Sequence of two alleles responsible for Gaucher disease. , 1990, DNA and cell biology.

[17]  G. Grabowski,et al.  Analyses of catalytic activity and inhibitor binding of human acid beta-glucosidase by site-directed mutagenesis. Identification of residues critical to catalysis and evidence for causality of two Ashkenazi Jewish Gaucher disease type 1 mutations. , 1990, The Journal of biological chemistry.

[18]  N. Firon,et al.  Genotype assignment in Gaucher disease by selective amplification of the active glucocerebrosidase gene. , 1990, American journal of human genetics.

[19]  M. Horowitz,et al.  Acid β-Glucosidase: Enzymology and Molecular Biology of Gaucher Diseas , 1990 .

[20]  M. Horowitz,et al.  Acid beta-glucosidase: enzymology and molecular biology of Gaucher disease. , 1990, Critical reviews in biochemistry and molecular biology.

[21]  E. Wiemer,et al.  Presence of peroxisomal membrane proteins in liver and fibroblasts from patients with the Zellweger syndrome and related disorders: evidence for the existence of peroxisomal ghosts. , 1989, European journal of cell biology.

[22]  E. Beutler,et al.  PREDICTION OF SEVERITY OF GAUCHER'S DISEASE BY IDENTIFICATION OF MUTATIONS AT DNA LEVEL , 1989, The Lancet.

[23]  B. Theophilus,et al.  Gaucher disease: molecular heterogeneity and phenotype-genotype correlations. , 1989, American journal of human genetics.

[24]  E. Bieberich,et al.  Intracellular activity of lysosomal glucosylceramidase measured with 4-nonylumbelliferyl beta-glucoside. , 1989, Biological chemistry Hoppe-Seyler.

[25]  S. Tsuji,et al.  Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[26]  G. Legler.  β-Glucocerebrosidase: Mechanistic Studies With Covalent and Non-Covalent Inhibitors , 1988 .

[27]  S. Tsuji,et al.  A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease. , 1987, The New England journal of medicine.

[28]  S. Brul,et al.  Relationship between the two immunologically distinguishable forms of glucocerebrosidase in tissue extracts. , 1987, European journal of biochemistry.

[29]  R. Desnick,et al.  Human acid beta-glucosidase. Use of conduritol B epoxide derivatives to investigate the catalytically active normal and Gaucher disease enzymes. , 1986, The Journal of biological chemistry.

[30]  J. Barranger,et al.  A procedure for the rapid purification in high yield of human glucocerebrosidase using immunoaffinity chromatography with monoclonal antibodies. , 1986, Analytical biochemistry.

[31]  E. Beutler,et al.  Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[32]  E. Ginns,et al.  The occurrence of two immunologically distinguishable beta-glucocerebrosidases in human spleen. , 1985, European journal of biochemistry.

[33]  S. Gatt,et al.  Gaucher disease types 1, 2, and 3: differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine. , 1985, American journal of human genetics.

[34]  D. Wenger,et al.  Studies on a sphingolipid activator protein (SAP-2) in fibroblasts from patients with lysosomal storage diseases, including Niemann-Pick disease Type C. , 1985, Clinica chimica acta; international journal of clinical chemistry.

[35]  E. Ginns,et al.  Mutations of glucocerebrosidase: discrimination of neurologic and non-neurologic phenotypes of Gaucher disease. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[36]  P. D. de Groot,et al.  Accumulation of weak bases in relation to intralysosomal pH in cultured human skin fibroblasts. , 1981, Biochimica et biophysica acta.

[37]  B Poole,et al.  Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[38]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.